

Table S1: Genes associated with mandibulo-facial and/or ear malformations analysed by next generation sequencing*.

Gene	Target region (bp)	Coverage (%)
<i>B3GALTL</i>	1797	100
<i>CHD7</i>	9778	99,89
<i>DHODH</i>	1368	100
<i>EDN1</i>	739	100
<i>EFTUD2</i>	3459	100
<i>EYA1</i>	2281	100
<i>FGF10</i>	687	100
<i>FGF3</i>	780	100
<i>FGFR2</i>	3324	100
<i>FGFR3</i>	3360	100
<i>GJA1</i>	1169	100
<i>GNAI3</i>	1259	100
<i>NFIX</i>	1847	100
<i>PLCB4</i>	4375	99,73
<i>POLRIC</i>	1348	99,70
<i>POLRID</i>	825	100
<i>SALL1</i>	4039	100
<i>SALL4</i>	3242	100
<i>SEMA3E</i>	2693	100
<i>SF3B4</i>	1395	100
<i>SIX1</i>	895	100
<i>SIX5</i>	2280	99,82
<i>TCOF1</i>	5159	100
<i>TFAP2A</i>	1897	100
<i>TSHZ1</i>	3119	100
Gene Panel	63115	99,95

* A custom panel for the targeted enrichment of 25 genes associated with mandibulo-facial and/or ear malformations was designed using the SureDesign software v3.0.3.1 (Agilent Technologies, Santa Clara, CA, United States). The gene panel contained 3670 amplicons and the coverage of the target regions (coding sequences and 10 bp flanking sequences) was 99.95 %. The target sequences of the investigated genes were isolated and captured using the HaloPlex Target Enrichment system (Agilent Technologies).

Table S2: Variants identified in patient P1 in genes involved in cranio-facial and/or ear malformations analysed by next generation sequencing.

Gene	HGVS (Genomic)	HGVS (Coding)	HGVS (Protein)	Read Depth	Allele Frequency	HOM/HET	dbSNP	MAF dbSNP
<i>SF3B4</i>	NC_000001.10:g.149898557G>A	NM_005850.4:c.417C>T	NP_005841.1:p.(Gly139=)	408	0.455	HET		
<i>FGFR3</i>	NC_000004.11:g.1803704T>C	NM_000142.4:c.882T>C	NP_000133.1:p.(Asn294=)	778	0.996	HOM	rs2234909	0.2075
<i>FGFR3</i>	NC_000004.11:g.1807894G>A	NM_000142.4:c.1953A>G	NP_000133.1:p.(Thr651=)	337	0.997	HOM	rs7688609	0.0439
<i>TCOF1</i>	NC_000005.9:g.149772280C>G	NM_000356.3:c.3296C>G	NP_000347.2:p.(Pro1099Arg)	465	0.489	HET	rs1136103	0.0815
<i>EDN1</i>	NC_000006.11:g.12294258A>G	NM_001955.4:c.318A>G	NP_001946.3:p.(Glu106=)	428	0.998	HOM	rs5369	0.0986
<i>EDN1</i>	NC_000006.11:g.12296255G>T	NM_001955.4:c.594G>T	NP_001946.3:p.(Lys198Asn)	360	0.446	HET	rs5370	0.2474
<i>SEMA3E</i>	NC_000007.13:g.83029438C>T	NM_012431.2:c.1272G>A	NP_036563.1:p.(Leu424=)	1399	0.999	HOM	rs2722974	0.3395
<i>SEMA3E</i>	NC_000007.13:g.83037751C>A	NM_012431.2:c.603G>T	NP_036563.1:p.(Ala201=)	524	0.998	HOM	rs2722985	0.4437
<i>EYAI</i>	NC_000008.10:g.72111599A>G	NM_000503.5:c.1755T>C	NP_000494.2:p.(His585=)	267	0.481	HET	rs10103397	0.4766
<i>FGFR2</i>	NC_000010.10:g.123239112G>A	NM_001144915.1:c.2107C>T	NP_001138387.1:p.(Leu703=)	186	0.46	HET	rs1047057	0.4143
<i>FGFR2</i>	NC_000010.10:g.123298158T>C	NM_000141.4:c.696A>G	NP_000132.3:p.(Val232=)	484	0.495	HET	rs1047100	0.2047
<i>POLR1D</i>	NC_000013.10:g.28239940G>C	NM_152705.2:c.219G>C	NP_689918.1:p.(Ala73=)	535	0.481	HET	rs11029	0.2578
<i>POLR1D</i>	NC_000013.10:g.28239970G>A	NM_152705.2:c.249G>A	NP_689918.1:p.(Pro83=)	536	0.499	HET	rs14105	0.3718
<i>B3GALTL</i>	NC_000013.10:g.31821240C>T	NM_194318.3:c.347+4C>T		743	0.48	HET	rs9564692	0.496
<i>B3GALTL</i>	NC_000013.10:g.31821992T>C	NM_194318.3:c.348T>C	NP_919299.3:p.(His116=)	356	0.997	HOM	rs4943266	0.0246
<i>B3GALTL</i>	NC_000013.10:g.31891746G>A	NM_194318.3:c.1108G>A	NP_919299.3:p.(Glu370Lys)	119	0.417	HET	rs1041073	0.3333
<i>SALL1</i>	NC_000016.9:g.51171175C>T	NM_002968.2:c.3823G>A	NP_002959.2:p.(Val1275Ile)	429	0.998	HOM	rs4614723	0.0132
<i>SALL1</i>	NC_000016.9:g.51173559G>A	NM_002968.2:c.2574C>T	NP_002959.2:p.(Leu858=)	851	0.998	HOM	rs1965024	0.4613
<i>DHODH</i>	NC_000016.9:g.72042682A>C	NM_001361.4:c.19A>C	NP_001352.2:p.(Lys7Gln)	450	0.488	HET	rs3213422	0.4359
<i>EFTUD2</i>	NC_000017.10:g.42949808G>A	NM_004247.3:c.994+6C>T		310	0.479	HET	rs11654183	0.2426
<i>EFTUD2</i>	NC_000017.10:g.42961009C>T	NM_004247.3:c.426+8G>A		640	0.456	HET	rs2289677	0.4395
<i>PLCB4</i>	NC_000020.10:g.9288522G>A	NM_000933.3:c.61G>A	NP_000924.3:p.(Ala21Thr)	576	0.998	HOM	rs6077510	0.4714
<i>SALL4</i>	NC_000020.10:g.50406630T>G	NM_020436.3:c.2392A>C	NP_065169.1:p.(Ile798Leu)	278	0.534	HET	rs6091375	0.0657
<i>SALL4</i>	NC_000020.10:g.50407162T>C	NM_020436.3:c.1860A>G	NP_065169.1:p.(Thr620=)	459	0.485	HET	rs6021437	0.382
<i>SALL4</i>	NC_000020.10:g.50407502A>C	NM_020436.3:c.1520T>G	NP_065169.1:p.(Leu507Arg)	224	0.493	HET	rs6126344	0.3588
<i>SALL4</i>	NC_000020.10:g.50407966C>T	NM_020436.3:c.1056G>A	NP_065169.1:p.(Ala352=)	213	0.533	HET	rs13038893	0.2093
<i>SALL4</i>	NC_000020.10:g.50408482A>G	NM_020436.3:c.540T>C	NP_065169.1:p.(Asn180=)	304	0.997	HOM	rs6013281	0.0026

Table S3: *In silico* predictions of the effect of the c.417C>T variant in *SF3B4* exon 3 on splicing.

	Predicted Effect	Wild-type allele	Mutant allele
NNSPLICE v. 0.9	Activation of a cryptic exonic donor site	Splice site not detected	Score: 0.99
NetGene2 v. 2.4	Activation of a cryptic exonic donor site	Splice site not detected	Score: 0.83
Human Splicing Finder	Activation of a cryptic exonic donor site	HSF matrices score: 61.15 MaxEnt score : 0.87	HSF matrices score: 87.99 MaxEnt score: 8.63
	Alterarion of an exonic ESE site		ESE site broken